Nalaganje...
Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
Dysregulation of the MET tyrosine kinase receptor is a known oncogenic driver, and multiple genetic alterations can lead to a clinically relevant oncogenesis. Currently, a number of drugs targeting MET are under development as potential therapeutics for different cancer indications, including non-sm...
Shranjeno v:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2022-04-01
|
| Serija: | Cancers |
| Teme: | |
| Online dostop: | https://www.mdpi.com/2072-6694/14/9/2150 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|